Rubicon Research Limited — PPTs, 14-08-2026: Investor Presentation

Here's a summary of Rubicon Research Limited's investor presentation:

**1. Business Performance:**

Rubicon Research saw impressive revenue growth of 51.6% year-over-year in Q1 FY27, reaching ₹5,343 million. This was driven by strong performance across segments. The company's USD revenue also increased by 32% YoY to $55 million.

**2. Growth Drivers or Strategy:**

The company continues to focus on its specialty product portfolio, which contributed 36% to gross profit in Q1 FY27. They are strategically managing their manufacturing mix and giving up lower-margin business to improve reliance on own manufacturing capabilities for future growth.

**3. Recent Developments:**

Rubicon acquired a USFDA-approved manufacturing facility in New Jersey for $2.9 million, marking their first US manufacturing footprint. They also received two product approvals in Q1 FY27, maintaining a strong commercialization rate of 88%.

**4. Key Financial Metrics:**

Revenue from operations stood at ₹5,343 million in Q1 FY27, a 51.6% increase YoY. EBITDA was ₹1,312 million, up 64.6% YoY, and PAT was ₹848 million, a 95.8% increase YoY.

**5. Management Commentary / Outlook:**

The company expects strong revenue visibility in the coming quarters. They are raising their FY27 operating EBITDA margin guidance to at least 23%, up from the previous 22-23% range, despite planned investments in new initiatives. The Pithampur plant is on track for ramp-up from Q1CY27.